Patents by Inventor Marc E. Rothenberg

Marc E. Rothenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020151064
    Abstract: A method of regulating CCR3 expression by transcriptional and mRNA control. In one embodiment, regulation occurs in a non-promoter, regulatory region of the CCR3 gene, such as untranslated exons 1, 2, and/or 3. This type of regulation has a preferential effect on eosinophilic cells; such selectivity advantageously produces less deleterious side effects when administered in a pharmaceutical preparation. Regulation of CCR3 expression by promoter targeting also presents a method to reduce CCR3 expression in a cell-specific or nonspecific manner. Other types of regulatory compounds do not demonstrate such a preferential effect. Because CCR3 is expressed on cells involved in inflammatory reactions, regulations of CCR3 provides an intervention site for asthma, as well as other allergic, inflammatory and hypersensitivity reactions, eosinophil-mediated diseases, and infectious disorders.
    Type: Application
    Filed: February 5, 2002
    Publication date: October 17, 2002
    Applicant: Children's Hospital Medical Center
    Inventors: Marc E. Rothenberg, Nives Zimmermann
  • Patent number: 6358697
    Abstract: A method and composition to target compounds into cells such as eosinophils. A ligand for a CCR-3 eosinophil surface receptor is provided under conditions to bind to the receptor and cause internalization of the ligand-CCR-3 complex. A compound, such as a drug in an active or inactive form, may be bound to the ligand and delivered to an intracellular site of the cell where it may subsequently become activated. The methods and compositions may be used to treat a variety of eosinophil-mediated disorders, for example, allergies.
    Type: Grant
    Filed: April 21, 1999
    Date of Patent: March 19, 2002
    Assignee: Children's Hospital Medical Center
    Inventors: Marc E. Rothenberg, Nives Zimmermann
  • Publication number: 20010055564
    Abstract: A method and composition to target compounds into cells such as eosinophils. A ligand for a CCR-3 eosinophil surface receptor is provided under conditions to bind to the receptor and cause internalization of the ligand-CCR-3 complex. A compound, such as a drug in an active or inactive form, may be bound to the ligand and delivered to an intracellular site of the cell where it may subsequently become activated. The methods and compositions may be used to treat a variety of eosinophil-mediated disorders, for example, allergies.
    Type: Application
    Filed: April 21, 1999
    Publication date: December 27, 2001
    Inventors: MARC E. ROTHENBERG, NIVES ZIMMERMANN